A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

NCT04590599 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

205

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cervical Cancer

Interventions

DRUG: IBI310
DRUG: Placebo
DRUG: Sintilimab

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.